《大行報告》高盛:統一(00220.HK)面臨成本壓力趨升 降目標價至7.2元
高盛發表報告,將統一企業中國(00220.HK)2022年至2024年的每股盈利預測分別下調12%至14%,以反映成本壓力上升和對銷售費用更嚴格的控制。目前預計2022年收入增長爲7%,純利倒退4%。基於17倍的2022年至2023年預測市盈率,目標價由7.9元下調至爲7.2元,評級爲「中性」。
高盛指,統一去年收入按年增10.8%,純利按年跌近8%。展望未來,歸功於統一在擴大銷售點和餐飲渠道覆蓋率等努力,高盛預計飲料業務收入可以繼續保持相對強勁的高單位數增長,其中果汁和奶茶將引領增長。同時預計在優質產品組合的推動下,即食麪業務將實現中單位數的收入增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.